A 2025 comprehensive review in Medical Science Monitor covering studies from 20162025 confirmed that GHK-Cu-based formulations enhance fibroblast migration, ECM remodelling, collagen and elastin synthesis, and wound closure across multiple model types
In human growth-hormone-deficiency trials using recombinant native IGF-1 (mecasermin, brand name Increlex), the approved dose range is 0.04-0.12 mg/kg twice daily by subcutaneous injection, titrated to IGF-1 levels in the age- and sex-normalised reference range [15]
Ritzel R, rskov C, Holst JJ, Nauck MA
KPV A short peptide commonly discussed for inflammation-related, skin and digestive wellness pathways
Fifty of the 173 users discontinued the agents before the 1-year study period was up, most often for gastrointestinal symptoms and "insurance issues." Limitations to the study included its single-center, retrospective design and small sample size